Erondu–Cymet syndrome
Erondu–Cymet syndrome is a rare genetic disorder characterized by a combination of neurological and musculoskeletal abnormalities. The syndrome was first described by Dr. Erondu and Dr. Cymet in the early 21st century.
Presentation[edit]
Individuals with Erondu–Cymet syndrome typically present with a range of symptoms that may include muscle weakness, spasticity, and joint contractures. These symptoms often lead to difficulties with mobility and coordination. Additionally, affected individuals may exhibit intellectual disability and developmental delay.
Genetics[edit]
Erondu–Cymet syndrome is believed to follow an autosomal recessive inheritance pattern. This means that an individual must inherit two copies of the mutated gene, one from each parent, to be affected by the disorder. The specific gene or genes involved in Erondu–Cymet syndrome have not yet been identified.
Diagnosis[edit]
The diagnosis of Erondu–Cymet syndrome is primarily based on clinical evaluation and the presence of characteristic symptoms. Genetic testing may be used to confirm the diagnosis, especially in cases where there is a known family history of the disorder.
Management[edit]
There is currently no cure for Erondu–Cymet syndrome. Management of the condition focuses on alleviating symptoms and improving the quality of life for affected individuals. This may include physical therapy, occupational therapy, and the use of assistive devices to aid mobility. In some cases, surgical intervention may be necessary to correct severe joint contractures.
Prognosis[edit]
The prognosis for individuals with Erondu–Cymet syndrome varies depending on the severity of the symptoms. Early intervention and supportive care can significantly improve outcomes and help individuals lead more independent lives.
Related Pages[edit]
- Genetic disorder
- Neurological disorder
- Musculoskeletal disorder
- Autosomal recessive
- Physical therapy
- Occupational therapy
- Assistive device
- Surgical intervention

This article is a genetic disorder stub. You can help WikiMD by expanding it!
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian